Selective progesterone receptor modulators
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Review of recent data from clinical trials and descriptions of endometrial morphology with administration of selective progesterone receptor modulators (SPRMs). RECENT FINDINGS: Recent reports concerning administration of SPRMs, specifically the efficacy of ulipristal acetate in reducing fibroid size and rapid control of menstrual blood loss, have renewed clinical interest in this class of compound. Histological data from studies with SPRMs report that this class of drugs is associated with progesterone receptor modulator-associated endometrial changes. Data on mechanisms of action are lacking. The antagonistic progesterone effect of SPRMs has shown promising results in animal studies with endometriosis. Sex steroid receptor effects of PRMs outside the reproductive tract raise the potential for use in neurology and oncology, and although there are several randomized trials in these areas, there are limited small studies published to date. SUMMARY: The SPRM ulipristal acetate is an effective treatment for preoperative treatment of fibroids and a reliable emergency contraceptive. This class of compounds holds the potential for long-term effective medical management of fibroids and may have utility in the management of other sex steroid-dependent conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853 · cited 1×
“However, approximately 20% will relapse [33], and radiotherapy, whilst often achieving control, can take several years to become effective.”
BackgroundProgestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Mei, L., Bao, J., Tang, L., Zhang, C., Wang, H., Sun, L., Ma, G., Huang, L., Yang, J., Zhang, L., et al. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.01.012 · Cited by 36
Huniadi, C. A., Pop, O. L., Antal, T. A., & Stamatian, F. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.03.022 · Cited by 35
Research works printed but not linked: 39
- Mutter, 2008, The spectrum of endometrial pathology induced by progesterone receptor modulators., Mod Pathol, 21, 591, 10.1038/modpathol.2008.19 · DOI · Paper page
- Williams, 2007, The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata., Hum Reprod, 22, 1696, 10.1093/humrep/dem026 · DOI · Paper page
- Engman, 2009, Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial., Hum Reprod, 24, 1870, 10.1093/humrep/dep100 · DOI · Paper page
- Wilkens, 2009, Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene., PTEN Hum Reprod, 24, 1036, 10.1093/humrep/den494 · DOI
- Williams, 2012, Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate., Int J Gynecol Pathol, 31, 556, 10.1097/PGP.0b013e318251035b · DOI · Paper page
- Donnez, 2014, Long-term treatment of uterine fibroids with ulipristal acetate., Fertil Steril, 101, 1565, 10.1016/j.fertnstert.2014.02.008 · DOI · Paper page
- Maruo, 2000, Effects of progesterone on uterine leiomyoma growth and apoptosis., Steroids, 65, 585, 10.1016/S0039-128X(00)00171-9 · DOI
- Talaulikar, 2012, Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids., Eur J Obstet Gynecol Reprod Biol, 165, 135, 10.1016/j.ejogrb.2012.07.023 · doi:10.1016/j.ejogrb.2012.07.023
- Donnez, 2012, Ulipristal acetate versus placebo for fibroid treatment before surgery., N Engl J Med, 366, 409, 10.1056/NEJMoa1103182 · DOI · Paper page
- Donnez, 2012, Ulipristal acetate versus leuprolide acetate for uterine fibroids., N Engl J Med, 366, 421, 10.1056/NEJMoa1103180 · DOI · Paper page
- Chabbert-Buffet, 2012, The immninent dawn of SPRMs in obstetrics and gynecology., Mol Cell Endocrinol, 358, 232, 10.1016/j.mce.2012.02.021 · DOI
- Tristan, 2012, Mifepristone for uterine fibroids., Cochrane Database Syst Rev, 8, CD007687
- Shen, 2013, Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis., Fertil Steril, 100, 1722, 10.1016/j.fertnstert.2013.08.039 · DOI
- Wilkens, 2008, Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy., J Clin Endocrinol Metab, 93, 4664, 10.1210/jc.2008-1104 · DOI · Paper page
- Horak, 2012, Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo., Int J Endocrinol, 2012, 436174, 10.1155/2012/436174 · DOI
- Creinin, 2006, Progesterone receptor modulator for emergency contraception: a randomized controlled trial., Obstet Gynecol, 108, 1089, 10.1097/01.AOG.0000239440.02284.45 · DOI · Paper page
- Brache, 2013, Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens., Contraception, 88, 611, 10.1016/j.contraception.2013.05.010 · DOI
- Brache, 2012, Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women., Contraception, 85, 480, 10.1016/j.contraception.2011.10.003 · DOI
- Brown, 2002, Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5mg per day for 120 days., J Clin Endocrinol Metab, 87, 63, 10.1210/jcem.87.1.8140 · DOI
- Lakha, 2007, A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)., Hum Reprod, 22, 2428, 10.1093/humrep/dem177 · DOI
- Stoeckemann, 1995, Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats., Hum Reprod, 10, 3264, 10.1093/oxfordjournals.humrep.a135900 · DOI · Paper page
- Li, 2012, Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model., Arch Gynecol Obstet, 286, 939, 10.1007/s00404-012-2379-2 · DOI
- Cohan, 2014, Pasireotide and mifepristone: new options in the medical management of Cushings disease., Endocr Pract, 20, 84, 10.4158/EP13127.RA · DOI
- Debono, 2013, Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study., PLoS One, 8, e60984, 10.1371/journal.pone.0060984 · DOI · Paper page
- Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk., J Am Med Assoc, 283, 485, 10.1001/jama.283.4.485 · DOI · Paper page
- Klijn, 2000, Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer., Steroids, 65, 825, 10.1016/S0039-128X(00)00195-1 · DOI
- Poole, 2006, Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist., Science, 314, 1467, 10.1126/science.1130471 · DOI · Paper page
- Robertson, 1999, Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer., Eur J Cancer, 35, 214, 10.1016/S0959-8049(98)00388-8 · DOI
- Communal, 2012, Ulipristal acetate does not impact human normal breast tissue., Hum Reprod, 27, 2785, 10.1093/humrep/des221 · DOI
- Moe, 2009, High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis., Anticancer Res, 29, 1053
- Jurado, 2009, Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study., Oncol Rep, 22, 1237
- El Etreby, 2000, Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice., Prostate, 42, 99, 10.1002/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(20000201)42:2<99::aid-pros3>3.0.co;2-i
- Tieszen, 2011, Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and nonreproductive origin regardless of progesterone receptor expression., BMC Cancer, 11, 207, 10.1186/1471-2407-11-207 · DOI
- Goyeneche, 2007, Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo., Clin Cancer Res, 13, 3370, 10.1158/1078-0432.CCR-07-0164 · doi:10.1158/1078-0432.ccr-07-0164
- Goyeneche, 2012, Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2., Invest New Drugs, 30, 967, 10.1007/s10637-011-9655-z · DOI
- Hernandez-Hernandez, 2012, Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines., J Steroid Biochem Mol Biol, 132, 127, 10.1016/j.jsbmb.2012.04.005 · DOI
- Ramaswamy, 2012, Study of effectiveness of mifepristone for glioma cell line growth suppression., Br J Neurosurg, 26, 336, 10.3109/02688697.2011.629696 · DOI
- Gamarra-Luques, 2012, Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy., BMC Cancer, 12, 200, 10.1186/1471-2407-12-200 · DOI
- Li, 2013, Mifepristone sensitizing cisplatin for cervical adenocarcinoma HeLa cell sensitivity to chemotherapy and its mechanism., Eur J Gynaecol Oncol, 34, 142
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Endometriosis and nuclear receptors
Yilmaz, B. D., & Bulun, S. E. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz005 · Cited by 243
Role of medical therapy in the management of uterine adenomyosis
Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.013 · Cited by 231
Metadata
- Authors
- Whitaker, L. H. R., Williams, A. R. W., & Critchley, H. O. D.
- Venue
- Current Opinion in Obstetrics & Gynecology
- Published
- 2014-08
- Volume
- 26
- Issue
- 4
- Pages
- 237-242
- ISSN
- 1040-872X (ISSN-L)
- OpenAlex
- W1988595534
- Cited by
- 35
- References
- 5
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective progesterone receptor modulators. https://app.cochat.ai/papers/10.1097/gco.0000000000000082
- The paper
- Whitaker, L. H. R., Williams, A. R. W., & Critchley, H. O. D. (2014). Selective progesterone receptor modulators. Current Opinion in Obstetrics & Gynecology. https://doi.org/10.1097/gco.0000000000000082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.